How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely PerformedVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
Dr Sibylle Loibl explains how fulvestrant (with or without palbociclib) fits in the treatment paradigm for patients with HR+/ HER2-negative metastatic breast cancer.